Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study

Cover Page

Cite item

Full Text

Abstract

Recent advances in the diagnosis and understanding of follicular lymphoma (FL) pathogenesis have had a significant impact on therapeutic tactics. The life expectancy of patients has increased significantly. Currently, the 5-year overall survival of FL patients achieved 90 %, and its median is approaching 20 years. However, FL remains an incurable disease with periods of remission and relapse, requiring multiple therapy courses throughout the patient’s life.

The main problem is the treatment of patients with refractory/relapsed forms, especially after 3rd line of therapy, as well as with a primarily resistant course and early (in the first 2 years) relapses. Therefore, despite the indolent FL course in most patients, there remains a need for new drugs that can ensure increased treatment efficacy with minimal toxicity and simultaneously maintain a high quality of life, mainly in the presence of primary refractoriness, early progression and in later lines of therapy. In recent years, new targeted drugs have been studied – phosphoinositide 3-kinase, enhancer of zeste homolog 2 inhibitors, as well as immunological drugs (CAR-T therapy (CAR – chimeric antigen receptor) and bispecific antibodies).

The article presents the possibilities of treatment for refractory/relapsed FL as 3rd and subsequent therapy lines.

About the authors

Ya. V. Krylova

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: yana.bloodgem@gmail.com
ORCID iD: 0000-0001-7177-4706

Yana V. Krylova 

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

E. V. Kondakova

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0001-9155-1737

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

A. N. Gavrilenko

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

A. M. Chekalov

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-4923-6773

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

L. V. Fedorova

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-3275-219X

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

L. V. Stelmakh

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

E. V. Babenko

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-3367-4936

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

T. S. Shchegoleva

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-2901-1948

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

A. A. Gusak

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-4275-3911

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

V. V. Baykov

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-9191-5091

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

N. B. Mikhailova

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-8153-8122

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

A. D. Kulagin

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-9589-4136

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

References

  1. Babicheva L.G., Poddubnaya I.V. First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice. Sovremennaya onkologiya = Journal of Modern Oncology 2020;22(2):119–25. (In Russ.). doi: 10.26442/18151434.2020.2.200125
  2. Tan D., Horning S.J., Hoppe R.T. et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 2013;122(6): 981–7. doi: 10.1182/blood-2013-03-491514
  3. Casulo C. Upfront identification of high-risk follicular lymphoma. Hematol Oncol 2021;39(Suppl 1):88–93. doi: 10.1002/hon.2852
  4. Casulo C., Dixon J.G., Le-Rademacher J. et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood 2022;139(11): 1684–93. doi: 10.1182/blood.2020010263
  5. Sarkozy C., Maurer M.J., Link B.K. et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol 2019;37(2):144–52. doi: 10.1200/JCO.18.00400
  6. Batlevi C.L., Sha F., Alperovich A. et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 2020;10(7):74. doi: 10.1038/s41408-020-00340-z
  7. Casulo C., Larson M.C., Lunde J.J. et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol 2022;9(4):e289–300. doi: 10.1016/S2352-3026(22)00033-3
  8. Brad S., Kahl M.D., Anik R. et al. Efficacy outcomes of treatments for double relapsed/refractory follicular lymphoma (R/R FL): a systematic literature review. Blood 2020;136(Suppl 1):42–43. doi: 10.1182/blood-2020-136228
  9. Gopal A.K., Kahl B.S., Flowers C.R. et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 2017;129:3037–9. doi: 10.1182/blood-2016-12-757740
  10. Flinn I.W., Miller C.B., Ardeshna K.M. et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent nonHodgkin lymphoma. J Clin Oncol 2019;37:912–22. doi: 10.1200/JCO.18.00915
  11. Dreyling M., Santoro A., Mollica L. et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol 2020;95:362–71. doi: 10.1002/ajh.25711
  12. Morschhauser F., Tilly H., Chaidos A. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21(11):1433–42. doi: 10.1016/S1470-2045(20)30441-1
  13. Jacobson C.A., Chavez J.C., Sehgal A.R. et al. Axicabtagene ciloleucel in relapsed or refractory indolent nonHodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91–103. doi: 10.1016/S1470-2045(21)00591-X
  14. Fowler N.H., Dickinson M., Dreyling M. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28(2):325–32. doi: 10.1038/s41591-021-01622-0
  15. Morschhauser F., Dahiya S., Palomba M.L. et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study [published correction appears in Nat Med 2024]. Nat Med 2024. doi: 10.1038/s41591-024-02986-9
  16. Mikhael J., Fowler J., Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol Pract 2022;18(12):800–7. doi: 10.1200/OP.22.00315
  17. Potnis K.C., Di M., Isufi I. et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv 2023;7(5):801–10. doi: 10.1182/bloodadvances.2022008097
  18. Fowler N.H., Dickinson M., Ghosh M. et al. Assessment of healthcare resource utilization and hospitalization costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with tisagenlecleucel: results from the ELARA study. Transplant Cell Ther 2023;29(1):60.e1–4. doi: 10.1016/j.jtct.2022.09.022
  19. Ferl G.Z., Reyes A., Sun L.L. et al. A preclinical population pharmacokinetic model for anti-CD20/CD3 T-cell-dependent bispecific antibodies. Clin Transl Sci 2018;11(3):296–304. doi: 10.1111/cts.12535
  20. Sun L.L., Ellerman D., Mathieu M. et al. Anti-CD20/CD3 T celldependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med 2015;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802
  21. Budde L.E., Sehn L.H., Matasar M. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055–65. doi: 10.1016/S1470-2045(22)00335-7
  22. Compassionate use treatment with mosunetuzumab for patients with relapsed/refractory follicular lymphoma (r/r FL) (AG42295). Guidance Document, version 3.0. 2021.
  23. Cheah C.Y., Bartlett N.L., Assouline S. et al. P1124: Mosunetuzumab retreatment is effective and well-tolerated in patients with relapsed or refractory B-cell nonHodgkin lymphoma. Hemasphere 2022;6(Suppl):1014–5. doi: 10.1097/01.HS9.0000847364.49527.45
  24. Assouline S., Bartlett N.L., Matasar M. et al. Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated r/r FL after ≥3 years of follow-up: subgroup analysis of a pivotal phase II study. EHA Library 2024;422337:S233.
  25. Sehn L.H., Bartlett N.L., Matasar M. et al. Mosunetuzumab demonstrates durable responses in patients with relapsed and/or refractory follicular lymphoma who have received ≥2 prior therapies: updated analysis of a pivotal phase II study. Hemasphere 2023;7 (Suppl 3):e36694eb. doi: 10.1097/01.HS9.0000971208.36694.eb
  26. Kanters S., Ball G., Kahl B. et al. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. BMC Cancer 2023;23(1):74. doi: 10.1186/s12885-023-10546-6
  27. Longhitano A.P., Slavin M.A., Harrison S.J., Teh B.W. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Rev 2021;49:100810. doi: 10.1016/j.blre.2021.100810

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.